Abstract
The discovery of endothelial progenitor cell (EPC) a decade ago has refuted the previous belief that vasculogenesis only occurs during embryogenesis. The reduced circulating concentration of EPCs is a surrogate marker of endothelial function and has been implicated in the pathogenesis of many vascular diseases. To date, the therapeutic benefit of neovascularization in ischaemic conditions in a non-diabetic setting has been demonstrated. This article aims to review the biology of EPCs in the diabetic setting with special emphasis on the effects of cardiovascular risk factor modification on EPC phenotype and methods to reverse or augment EPC dysfunction. The potential of the use of EPCs in the treatment of the diabetic vascular dysfunction will also be discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 353-366 |
| Number of pages | 14 |
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 10 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 May 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Diabetes mellitus
- Endothelial progenitor cells
- Vascular diseases
Authors (Note for portal: view the doc link for the full list of authors)
- Authors
- Liew A;McDermott JH;Barry F;O'Brien T;
Fingerprint
Dive into the research topics of 'Endothelial progenitor cells for the treatment of diabetic vasculopathy: Panacea or Pandora's box?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver